P685 Healthcare resource use associated with ferric maltol and IV iron treatment for iron deficiency anaemia in patients with inflammatory bowel diseaseECCO'20 Vienna
2020
P686 Expression of CD39 ectonucleotidase on regulatory T cells and on T helper 17 cells in children with IBD receiving anti-TNF therapy
ECCO'20 Vienna
2020
P687 Early and sustained improvement in stool frequency and rectal bleeding following 52 weeks of mirikizumab treatment
ECCO'20 Vienna
2020
P689 Patient-reported outcomes (PRO-2) and intestinal ultrasound in ulcerative colitis patients: subanalysis of the TRUST&UC study cohort
ECCO'20 Vienna
2020
P691 Corticosteroids usage in patients with inflammatory bowel disease: Results of a multi-national audit in Asia
ECCO'20 Vienna
2020
P694 Validation of two commercial assays for therapeutic drug monitoring of adalimumab biosimilars
ECCO'20 Vienna
2020
P695 Vedolizumab induction and maintenance though levels and long-term clinical and biochemical status in inflammatory bowel disease
ECCO'20 Vienna
2020
P696 The usefulness to treatment enhancement for the patients of ulcerative colitis with clinical remission diagnosed as Mayo endoscopic subscore 1
ECCO'20 Vienna
2020
P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia
ECCO'20 Vienna
2020
P699 The concordance of Short Form-36 Health Survey scores with Mayo scores in the tofacitinib ulcerative colitis clinical programme
ECCO'20 Vienna
2020